

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

MEDICINE TO GO PHARMACIES, INC., on : Civil Action No. 2:16-cv-07717 (CCC)(MF)
behalf of plaintiff and the class members :
defined herein, :

Plaintiff,

v.

MACOVEN PHARMACEUTICALS, LLC,
PERNIX THERAPEUTICS HOLDINGS,
INC., and JOHN DOES 1-10,

Defendants.

REVISED SCHEDULING ORDER

THIS MATTER having come before the Court for a Revised Scheduling Order amending the Court's Initial Scheduling Order (DE 15), and for good cause shown:

IT IS on this 24 day of August, 2017

ORDERED THAT the Initial Scheduling Order is revised as follows:

1. The Court will conduct an in-person settlement conference **on October 3, 2017 at 10:30 a.m.**
2. Fact discovery is to remain open through **November 15, 2017**;
3. All affirmative expert reports shall be delivered by **December 13, 2017**, with depositions of those experts to be taken and completed within thirty (30) days of receipt of the report.
4. All responding expert reports shall be delivered by **January 13, 2018**, with depositions of those experts to be taken and completed within thirty (30) days of receipt of the report.
5. Any motions for class certification shall be filed by **March 26, 2018**.

All other deadlines and provisions in the Court's Initial Scheduling Order (DE 15) not addressed above remain unchanged.


Hon. Mark J. Denko, U.S. District Judge